Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.79 |
| ▸ | STK3 | Q13188 | 4/20 | 0.79 |
| ▸ | STK4 | Q13043 | 4/20 | 0.79 |
| ▸ | SRC | P12931 | 2/20 | 0.79 |
| ▸ | KDR | P35968 | 2/20 | 0.79 |
| ▸ | STK25 | O00506 | 1/20 | 0.79 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.79 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.79 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.79 |
| ▸ | STK17B | O94768 | 1/20 | 0.79 |
| ▸ | STK10 | O94804 | 1/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054544 | 0.93 | ERBB2 (0.69) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL10023955 | 0.92 | EGFR (0.73) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL14765641 | 0.92 | ERBB2 (0.67) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL29801657 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL29394766 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL15163655 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL29376313 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL571763 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL571762 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL15163654 | 0.89 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230201155-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | WYETH LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-10035788-B2 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035788-B2 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170320852-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC | 2017-11-09 | — | — | US | disclosed |
| US-20170320852-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC | 2017-11-09 | — | — | US | disclosed |
| US-20170231972-A1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | WYETH | 2017-08-17 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-8022216-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022216-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110195066-A1 | QUINOLINE INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110165257-A1 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | WYETH LLC (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110111018-A1 | COATED TABLET FORMULATIONS AND USES THEREOF | WYETH LLC (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2258698-A2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Wyeth LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009052264-A2 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165257-A1 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | CHEK1, MAP3K15, KIT | EGFR 51/4885ERBB2 31/4885STK3 158/4885 |
| US-20170231972-A1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | HK2, HKDC1, HK1 | EGFR 669/4885ERBB2 184/4885STK3 2127/4885 |
| US-20170320852-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, ERBB4, ALK | EGFR 1/4885ERBB2 7/4885STK3 392/4885 |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885STK3 469/4885 |
| US-10035788-B2 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | EGFR, ERBB4, ERBB3 | EGFR 1/4885ERBB2 4/4885STK3 436/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | EGFR 3656/4885ERBB2 3194/4885STK3 3024/4885 |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, ERBB4, ALK | EGFR 1/4885ERBB2 4/4885STK3 367/4885 |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | BTK, LCK, DSTYK | EGFR 228/4885ERBB2 52/4885STK3 366/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | EGFR 1032/4885ERBB2 240/4885STK3 2746/4885 |
| US-20230201155-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | RICTOR, MTOR, TFPI2 | EGFR 80/4885ERBB2 19/4885STK3 871/4885 |
| US-20110111018-A1 | COATED TABLET FORMULATIONS AND USES THEREOF | EGFR, NNT, ERBB3 | EGFR 1/4885ERBB2 46/4885STK3 789/4885 |
| US-20110195066-A1 | QUINOLINE INHIBITORS OF TYROSINE KINASE | ABL1, FLT3, BTK | EGFR 369/4885ERBB2 9/4885STK3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.